Abstract Library

#1425 Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate.

Introduction: Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Lucas C, Goodman S, Smith J, Burge M, Wyld D,

Keywords: lutetium, dosimetry, renal, gelatin, somatostatin,

#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC

Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Mottaghy F,

Keywords: PRRT, 90y-DOTATOC, dosimetry, 111in-octreotide, amino acids,

#238 Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?

Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Baum R,

Keywords: single kidney, non-functional kidney, peptide receptor radionuclide therapy, NET,